Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

Summary

The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.

Timeline

Start

2006-03

Primary completion

—

Completion

—

Drugs

Indications